@article{7c89a5072fb84290a4b62cd342be100b,
title = "Vorapaxar in the secondary prevention of atherothrombotic events",
abstract = "Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.",
keywords = "Aged, Brain Ischemia, Cardiovascular Diseases, Double-Blind Method, Female, Hemorrhage, Humans, Intracranial Hemorrhages, Kaplan-Meier Estimate, Lactones, Male, Middle Aged, Myocardial Infarction, Peripheral Arterial Disease, Platelet Aggregation Inhibitors, Pyridines, Receptor, PAR-1, Retreatment, Risk, Secondary Prevention, Stroke",
author = "Morrow, \{David A\} and Eugene Braunwald and Bonaca, \{Marc P\} and Ameriso, \{Sebastian F\} and Dalby, \{Anthony J\} and Fish, \{Mary Polly\} and Fox, \{Keith A A\} and Lipka, \{Leslie J\} and Xuan Liu and Nicolau, \{Jos{\'e} Carlos\} and Ophuis, \{A J Oude\} and Ernesto Paolasso and Scirica, \{Benjamin M\} and Jindrich Spinar and Pierre Theroux and Wiviott, \{Stephen D\} and John Strony and Murphy, \{Sabina A\} and \{TRA 2P–TIMI 50 Steering Committee and Investigators\} and Iversen, \{Helle Klingenberg\} and S{\o}ren Galatius",
year = "2012",
doi = "10.1056/NEJMoa1200933",
language = "English",
volume = "366",
pages = "1404--13",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",
}